TY - JOUR
T1 - Laboratory and clinical evaluation of RU 28965 in respiratory infections
AU - Shigeno, Yoshiteru
AU - Kakazu, Tomokazu
AU - Tamaki, Kazunori
AU - Fukuhara, Hiroshi
AU - Miyagi, Mustsuko
AU - Nakamura, Hiroki
AU - Kaneshima, Hiroshi
AU - Shimoji, Katsuyoshi
AU - Kitsukawa, Keizo
AU - Mori, Kenji
AU - Kinjo, Yutoku
AU - Saito, Atsushi
AU - Nakasone, Isamu
AU - Taira, Masayuki
AU - Kusano, Nobuchika
AU - Hokama, Seitetsu
AU - Irabu, Yuei
AU - Oshiro, Morio
PY - 1988
Y1 - 1988
N2 - RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2%(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.
AB - RU 28965, a new macrolide antibiotic, was basically and clinically evaluated with the following results. 1. Antimicrobial activity: the minimum Inhibitory concentrations (MICs) of RU 28965 against a total 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of erythromycin (EM) and cefaclor (CCL). RU 28965's antibacterial activity was equally or half as potent as that of EM against S.aureus, S.pneumoniae, B.catarrhalis and 1/2 or 1/4 as potent against H. influenzae. On the other hand, both antibiotics were poor against K.pneumoniae and P.aensginosa. 2. Clinical efficacy: RU 28965 was administered at a dailydose of 300 mg for 3~14 days to 15 patients with various respiratory infections. Clinical response was good 9, fair 2, poor 2 and not assessable 1; one dropped out. The overall efficacy rate was 69.2%(9/13 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of RU 28965. Three patients showed adverse reactions: diarrhea, eosinophilia, and minimal elevation of both S-GOT and S-GPT in 1 each. We therefore conclude that RU 28965 is a useful antibiotic in treating patients with respiratory infections.
UR - http://www.scopus.com/inward/record.url?scp=85004482986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85004482986&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.36.Supplement4_461
DO - 10.11250/chemotherapy1953.36.Supplement4_461
M3 - Article
AN - SCOPUS:85004482986
SN - 0009-3165
VL - 36
SP - 461
EP - 473
JO - Chemotherapy
JF - Chemotherapy
ER -
